Abstract：
Early-stage glottic laryngeal carcinoma refers to Tis-T2 lesions without cervical lymph nodes involvement and distant metastasis. Rosiglitazone facilitates expression of anti-inflammatory substances in the body, protecting immune system and improving patient\'s treatment efficacy and prognosis. We aimed to clarify the influence of rosiglitazone on prognosis of early-stage glottic laryngeal carcinoma. The control group received low-temperature plasma radiofrequency ablation and the observation group additionally received rosiglitazone; 4 mg, 2 times/day for 6 months. After treatment, the observation group showed reduction in the fundamental frequency perturbation and amplitude perturbation and increase in the harmonic-to-noise ratio relative to the control group. Total effective rate was 80.31% and 77.14% for observation and control groups, respectively (P > 0.05). Peripheral blood immune makers were higher in the observation group. The incidence rates of adverse reactions were lower in the observation group. The median survival time was 33 months in control group and 47 months in observation group (P < 0.05). The five-year survival rate was 77.14% in the observation group and 54.29% in the control group (P < 0.05). Rosiglitazone can prolong the survival of early-stage glottic laryngeal carcinoma patients, improving immune function and reducing adverse reactions during treatment.
摘要：
早期声门型喉癌是指Tis-T2病变，未涉及颈部淋巴结和远处转移。罗格列酮促进体内抗炎物质的表达，保护免疫系统，改善患者的治疗效果和预后。我们旨在阐明罗格列酮对早期声门型喉癌预后的影响。对照组接受低温等离子射频消融术,观察组在对照组基础上接受罗格列酮治疗;4mg,2次/天，持续6个月。治疗后,与对照组相比,观察组的基频扰动和振幅扰动减少,谐波噪声比增加.观察组和对照组的总有效率分别为80.31%和77.14%。分别为(P>0.05)。观察组外周血免疫标志物较高。观察组不良反应发生率较低。对照组中位生存时间为33个月,观察组中位生存时间为47个月,差异有统计学意义(P<0.05)。观察组5年生存率为77.14%,对照组为54.29%,差异有统计学意义(P<0.05)。罗格列酮可以延长早期声门型喉癌患者的生存期，改善免疫功能，减少治疗过程中的不良反应。
